Saturday, June 18th, 2016 - WiseGuyReports

WiseGuyReports.com adds“Nonalcoholic Steatohepatitis (NASH) Industry 2016 Market Leaders,Future Demand,Company Profiles and Industrial Overview Research Report”reports to its database.

COMPLETE REPORT DETAILS @ https://www.wiseguyreports.com/reports/global-nonalcoholic-steatohepatitis-nash-market-pipeline-analysis-drug-class-clinical-trials-and-geography-size-share-global-trends-company-profiles-demand-insights-analysis-research-report-opportunities-segmentation-and-forecast-2013-2020

Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase . Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Global non-alcoholic Steatohepatitis market is expected to garner $1693.2 million by 2020 growing at a CAGR of 25.6% during 2014-2020.

Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. The market growth is restricted by factors such as NASH’s complex and enigmatic physiological structure and inefficient diagnostics technology; these factors could also prolong the commercialization process for NASH therapeutics. Nevertheless, certain key players competing in the market are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. The results of a recent clinical trial conducted by Genfit satisfied concerns of the EMA (European Medicines Agency), regarding the efficacy and safety of GFT5o5 as therapeutics for NASH. The EMA finally recommended that the development of GFT5o5 as a therapeutic drug progress to Phase III of the clinical trial. Additionally, Dainippon Sumitomo Pharma (DSP), a partner of Intercept Pharmaceuticals, initiated a phase 2 clinical trial to test the safety and efficacy of one daily dose of OCA in 200 adult NASH patients. The trial is expected to be completed in the first half of 2016.

For more information or any query mail at [email protected]     

Geographically, the NASH therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Geographical analysis of NASH therapeutics is conducted with reference to research and commercialization. North America, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. It is also one of the regions with the most cases of NASH and other non-alcoholic fatty liver diseases. European countries are equally contributing to the growth of the NASH therapeutics market in terms of research and commercialization; however, failure to comply with regulations and decreased number of research initiatives causes them to be relegated to the second place in this market. With regard to developing economies, Asia-Pacific region is one of the fastest growing markets for NASH therapeutics and is expected to have a double digit growth rate during the analysis period. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people afflicted with these conditions- a number which is expected to increase up to 30 fold by 2030. Furthermore, the exorbitant price of the physical therapeutics currently used to treat fatty liver diseases is raising the demand for pharmaceutical therapies as they are comparatively economical.

KEY BENEFITS

  • Various opportunities for non alcoholic fatty liver disease therapeutics present in developed as well as developing economies are thoroughly assessed
  • Substitute treatments and their potential impact on NASH therapeutics are strategically quantified in the report
  • Opportunities from a business perspective latent in the Asia-Pacific region are brought to light
  • Market dimensions of diagnostic techniques used in NASH monitoring provide a clear outline of the NASH therapeutics research market
  • Geography-wise segmentation of clinical trials is conducted to provide strategic intelligence to the stakeholder
  • Pipeline analysis for the key NASH therapeutics under clinical research provides market intelligence needed for commercialization
  • Detailed analysis of market dynamics provides intelligence about market competencies according to segments
  • In depth analysis of key players operating in the fatty liver disease therapeutics market is conducted according to regions
  • Drivers and factors limiting market expansion are studied in detail
  • Comprehensive and quantitative data about changing market trends, competition and opportunities in NASH market is provided in the report
  • SWOT analysis of companies would help stakeholders make strategic decisions
  • Deep dive analysis of key market players and strategies adopted by them would provide valuable information regarding the top contenders in the market

REQUEST FOR SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/global-nonalcoholic-steatohepatitis-nash-market-pipeline-analysis-drug-class-clinical-trials-and-geography-size-share-global-trends-company-profiles-demand-insights-analysis-research-report-opportunities-segmentation-and-forecast-2013-2020

KEY DELIVERABLES

Global Non-alcoholic Steatohepatitis market is categorized into pipeline therapeutic types and geography.

MARKET BY THERAPEUTICS

  • GFT505
  • Obeticholic Acid (INT-747)
  • Simtuzumab and Liraglutide (Victoza)
  • Vitamin E
  • Pioglitazone
  • Placebo

MARKET BY GEOGRAPHY

  • North America NASH drugs market
    • GFT50
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo
  • Europe NASH drugs market 
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo
  • Asia-Pacific NASH drugs market 
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazon
    • Placebo
  • LAMEA NASH drugs market 
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo

CHECK DISCOUNT ON THIS REPORT @  https://www.wiseguyreports.com/check-discount/global-nonalcoholic-steatohepatitis-nash-market-pipeline-analysis-drug-class-clinical-trials-and-geography-size-share-global-trends-company-profiles-demand-insights-analysis-research-report-opportunities-segmentation-and-forecast-2013-2020

For more information or any query mail at [email protected]

Contact Profile

WiseGuyReports


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.


Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349
W: www.wiseguyreports.com/

Keywords

Nonalcoholic Steatohepatitis,Nonalcoholic Steatohepatitis Industry,Nonalcoholic Steatohepatitis Market,Nonalcoholic Steatohepatitis Market Trend,Nonalcoholic Steatohepatitis Industry Trends,Nonalcoholic Steatohepatitis Market Share,Nonalcoholic Steatohepa

Categories

Newsrooms

Sharing

More Formats